Other substances

Posaconazole

A triazole antifungal.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
1
 Clinical trials

General information

Posaconazole on PubChem

Marketed as

NOXAFIL; POSACONAZOLE; POSANOL

 

Structure image - Posaconazole

CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F

Supporting references

Link Tested on Impact factor Notes Publication date
Step toward repurposing drug discovery for COVID‐19 therapeutics through in silico approach
Spike protein 3CLpro PapainLpro RdRpol nsp3 nsp16 nsp9 nsp10 nsp4 Helicase (nsp19) Small molecule In silico 		in silico 1.90

Predicted to bind the SARS-CoV-2 helicase (nsp19).

 Nov/10/2020

AI-suggested references

Link Publication date
Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication.
Jul/31/2021
Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis.
Aug/25/2021
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
May/13/2021
Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern
Jan/15/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT05065658 Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients Recruiting Mar/01/2020 Dec/01/2022
  • Alternative id - 32-296 ex 19/20
  • Interventions - Drug: Posaconazole
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Medical University of Graz, Graz, Styria, Austria|University of Rennes, Rennes, France|San Martino Polyclinic Hospital IRCCS, Genova, Italy
  • Study designs - Observational Model: Case-Control|Time Perspective: Retrospective
  • Enrollment - 351
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of COVID-19 associated pulmonary aspergillosis (CAPA)|Survival at ICU discharge|Length of ICU stay|Mortality rate at 30 days|Mortality rate at 90 days
Export (.csv)